GLP-1 is a natural human hormone that regulates blood glucose levels. Scientists have now created long-lasting GLP-1 drugs ...

GLP-1 receptor agonists lead a new wave of therapeutic options that may benefit patients with osteoarthritis, according to ...

GLP-1–pathway agonists such as semaglutide and newer multi-agonists have transformed care for obesity and diabetes, yet developers still wrestle with durability, tissue targeting, and signal "bias." ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and alcohol-associated liver disease, as growing evidence suggests they reduce the ...

Recently, tennis legend Serena Williams opened up about using weight-loss medication, aiming to break the ‘stigma’ around such treatments. The 43-year-old, who has won 23 Grand Slam titles and is the ...

"Type 2 diabetes in children and teens is increasing at an alarming rate, yet treatment options are limited, and this patient population remains underserved," said Kenneth Custer, Ph.D., executive ...

HOUSTON -- Patients with polycythemia vera (PV) and a history of treatment with GLP-1 agonists had significantly lower rates of multiple adverse outcomes associated with the disease, a large ...

A popular class of therapies for treating diabetes and obesity may also have the potential to treat alcohol and drug ...

No significant association was observed between GLP-1 receptor agonists and an increased risk for suicide death, with an adjusted hazard ratio [aHR] of 1.25 (95% CI, 0.83-1.88). The aHR for the ...

GLP-1 drugs are expanding beyond diabetes to potentially reduce heart disease and improve sleep quality. Market for GLP-1 drugs is set to grow from $70 billion in 2025 to $157 billion by 2030, led by ...